The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.
We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.
Spellberg
Brad J
BJ
Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502, USA. bspellberg@labiomed.org
Ibrahim
Ashraf S
AS
Avenissian
Valentina
V
Filler
Scott G
SG
Myers
Carter L
CL
Fu
Yue
Y
Edwards
John E
JE
D000818:Animals; D002176:Candida albicans / Q000235:genetics / Q000276:immunology*; D002177:Candidiasis / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control*; D005656:Fungal Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
C093538:ALS1 protein, Candida albicans; D005656:Fungal Proteins; D005657:Fungal Vaccines; D010446:Peptide Fragments; D014614:Vaccines, Synthetic